Pfizer Stock: Paying Too Much To Boost Revenues (NYSE:PFE)


Businesswoman handshake and business people. Successful business concept.



I was initially interested in buying Pfizer (NYSE:PFE) but after deeper research, I got more and more reluctant to pull the trigger. So I am rating it a ‘Neutral/Hold’ for now. Here’s my narrative for Pfizer:

  1. Pfizer needs

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *